{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:27:09Z","timestamp":1786591629296,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10072-026-09233-8","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:08:32Z","timestamp":1784167712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement-mediated thrombotic microangiopathy presenting as atypical hemolytic uremic syndrome during disease-modifying therapy for multiple sclerosis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-7284","authenticated-orcid":false,"given":"Emine-Rabia","family":"Koc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7297-6200","authenticated-orcid":false,"given":"Asl\u0131han","family":"Bask\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-2317","authenticated-orcid":false,"given":"Furkan","family":"Saridas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-9692","authenticated-orcid":false,"given":"Aysegul","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"9233_CR1","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264:2351\u20132374. https:\/\/doi.org\/10.1007\/s00415-017-8594-9","journal-title":"J Neurol"},{"key":"9233_CR2","doi-asserted-by":"publisher","unstructured":"Maria HV et al (2025) Luis Gustavo Modelli de A, Maria Izabel Neves de Holan da B, Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN). Brazilian Journal of Nephrology. https:\/\/doi.org\/10.1590\/2175-8239-jbn-2024-0087en","DOI":"10.1590\/2175-8239-jbn-2024-0087en"},{"key":"9233_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and Treatment of Multiple Sclerosis. JAMA 325:765. https:\/\/doi.org\/10.1001\/jama.2020.26858","journal-title":"JAMA"},{"key":"9233_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186","author":"I Tramacere","year":"2016","unstructured":"Tramacere I, Benedetti MD, Capobussi M et al (2016) Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Reviews. https:\/\/doi.org\/10.1002\/14651858.CD012186","journal-title":"Cochrane Database Syst Reviews"},{"key":"9233_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/0971-4065.181453","volume":"27","author":"R Goli","year":"2017","unstructured":"Goli R, Mukku KK, Devaraju SBR, Uppin MS (2017) Acyclovir-induced thrombotic microangiopathy. Indian J Nephrol 27:131\u2013132. https:\/\/doi.org\/10.4103\/0971-4065.181453","journal-title":"Indian J Nephrol"},{"key":"9233_CR6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","volume":"89","author":"BM Jacobs","year":"2018","unstructured":"Jacobs BM, Ammoscato F, Giovannoni G et al (2018) Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry 89:1266\u20131271. https:\/\/doi.org\/10.1136\/jnnp-2017-317411","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9233_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1177\/13524585211022719","volume":"27","author":"K Sch\u00f6nfelder","year":"2021","unstructured":"Sch\u00f6nfelder K, Schuh H, Pfister F et al (2021) Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple Scler J 27:1960\u20131964. https:\/\/doi.org\/10.1177\/13524585211022719","journal-title":"Multiple Scler J"},{"key":"9233_CR8","doi-asserted-by":"publisher","first-page":"102023","DOI":"10.1016\/j.msard.2020.102023","volume":"41","author":"F Aruta","year":"2020","unstructured":"Aruta F, Iovino A, Costa C et al (2020) Lichenoid rash: A new side effect of oral Cladribine. Mult Scler Relat Disord 41:102023. https:\/\/doi.org\/10.1016\/j.msard.2020.102023","journal-title":"Mult Scler Relat Disord"},{"key":"9233_CR9","doi-asserted-by":"publisher","unstructured":"Rolfes L, Pfeuffer S, Hackert J et al (2021) Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment. Neurol Neuroimmunol Neuroinflamm 8:e990. https:\/\/doi.org\/10.1212\/NXI.0000000000000990","DOI":"10.1212\/NXI.0000000000000990"},{"key":"9233_CR10","doi-asserted-by":"publisher","first-page":"104459","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG et al (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459. https:\/\/doi.org\/10.1016\/j.msard.2022.104459","journal-title":"Mult Scler Relat Disord"},{"key":"9233_CR11","doi-asserted-by":"publisher","first-page":"106600","DOI":"10.1016\/j.msard.2025.106600","volume":"103","author":"A Albanese","year":"2025","unstructured":"Albanese A, Schiavetti I, Sormani MP (2025) Real-world experience with cladribine in the two years since treatment start: A systematic review and meta-analysis. Mult Scler Relat Disord 103:106600. https:\/\/doi.org\/10.1016\/j.msard.2025.106600","journal-title":"Mult Scler Relat Disord"},{"key":"9233_CR12","doi-asserted-by":"publisher","unstructured":"Saez-Calveras N, Stuve O (2022) The role of the complement system in Multiple Sclerosis: A review. Front Immunol 13:970486. https:\/\/doi.org\/10.3389\/fimmu.2022.970486","DOI":"10.3389\/fimmu.2022.970486"},{"key":"9233_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3390\/jcm14072527","volume":"14","author":"R-G Bogdan","year":"2025","unstructured":"Bogdan R-G, Anderco P, Ichim C et al (2025) Atypical Hemolytic Uremic Syndrome: A Review of Complement Dysregulation, Genetic Susceptibility and Multiorgan Involvement. J Clin Med 14:2527. https:\/\/doi.org\/10.3390\/jcm14072527","journal-title":"J Clin Med"},{"key":"9233_CR14","doi-asserted-by":"publisher","first-page":"175628642312006","DOI":"10.1177\/17562864231200627","volume":"16","author":"K Allen-Philbey","year":"2023","unstructured":"Allen-Philbey K, De Trane S, MacDougall A et al (2023) Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Ther Adv Neurol Disord 16:17562864231200628. https:\/\/doi.org\/10.1177\/17562864231200627","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09233-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09233-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09233-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:39:41Z","timestamp":1786588781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09233-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9233"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09233-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the institutional policies of Bursa Uludag University ethical approval is not required for single-patient case reports. The study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its later amendments.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for participation and for publication of this case report and any accompanying images.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The adverse event was formally reported to the national pharmacovigilance authority in accordance with pharmacovigilance regulations.","order":4,"name":"Ethics","label":"Pharmacovigilance reporting","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"631"}}